Hematology: An Annotated Bibliography of Recent Literature
Authors: HEMATOLOGY COMMITTEE
Journal: Annals of Internal Medicine (1979)

The Literature of Medicine1 May 1979Hematology: An Annotated Bibliography of Recent LiteratureReferences to Journal Articles and Other PapersHEMATOLOGY COMMITTEEHEMATOLOGY COMMITTEESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-90-5-860 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis bibliography includes references to 99 recently published journal papers and similar sources that represent important developments in the concept and practice of internal medicine. It has been compiled by the Hematology Committee as a part of the Medical Knowledge Self-Assessment Program V Syllabus.In preparing this bibliography, the committee reviewed MEDLINE†bibliographic printouts of journal articles published since the beginning of 1975 and also drew on sources in libraries of hospitals and other clinical institutions in the United States and Canada; thus, only papers in English are listed, and most are from American journals....Hematopoietic Stem Cells1. ADAMSONFIALKOWMURPHYPRCHALSTEINMANN JPSJL: Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 295:913-915, 1976 Another demonstration of the clonal nature of a myeloproliferative disorder. CrossrefMedlineGoogle Scholar2. BOGGS D: The pathogenesis and clinical patterns of blastic crisis of chronic myeloid leukemia. Semin Oncol 3:289-296, 1976 Description of the pathogenetic mechanisms, morphologic and chromosomal changes, clinical features, and treatment. MedlineGoogle Scholar3. CAMITTATHOMASNATHANSANTOSGORDON-SMITHGALERAPPEPORTSTORB BEDGERJR: Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 48:63-70, 1976 An important study on the role of marrow transplantation in the patient with severe aplastic anemia. The criteria for selecting such patients are described and the marked decrease in morbidity and mortality after transplantation documented. CrossrefMedlineGoogle Scholar4. CLINEGOLDE MD: Immune suppression of hematopoiesis. Am J Med 64:301-310, 1978 This balanced, well-written review on a subject of considerable controversy outlines the many ways in which the immune system might interact with hematopoiesis. CrossrefMedlineGoogle Scholar5. FIALKOWJACOBSONPAPAYANNOPOULOU PRT: Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63:125-130, 1977 One of several papers in which isozymes are used to demonstrate the clonal nature of the myeloproliferative disorders. The concept and its consequences are important. CrossrefMedlineGoogle Scholar6. GRABERKRANTZ SS: Erythropoietin and the control of red cell production. Annu Rev Med 29:51-66, 1978. Review of erythropoiesis, the action of erythropoietin, and the clonal capacity of erythroid progenitor cells (such as CFU-E and BFU-E). CrossrefMedlineGoogle Scholar7. METCALF D: In vitro cloning techniques for hemopoietic cells: clinical applications. Ann Intern Med 87:483-488, 1977 Describes the method for culturing different hematopoietic cells in vitro and the clinical information that can be obtained by culturing cells from patients with various diseases including leukemia, lymphoma, and polycythemia vera. LinkGoogle Scholar8. THOMASFEFERBUCKNERSTORB EACR: Current status of bone marrow transplantation for aplastic anemia and acute leukemia. Blood 49:671-681, 1977 Review of the principles of bone marrow transplantation, the results of transplantation for aplastic anemia and acute leukemia, and the problems associated with marrow transplantation and factors affecting patient survival. CrossrefMedlineGoogle Scholar9. ALLENSEETHARAMPODELLALPERS RBED: Effect of proteolytic enzymes on the binding of cobalamin to R protein and intrinsic factor. In vitro evidence that a failure to partially degrade R protein is responsible for cobalamin malabsorption in pancreatic insufficiency. J Clin Invest 61:47-54, 1978 This important paper helps clarify the function of "r" binders in the absorption of vitamin B12 (cobalamin) and explains some of the perturbations of intrinsic factor binding and the related role of normal pancreatic secretions. CrossrefMedlineGoogle Scholar10. AMMANNADDIEGOWARALUBINSMITHMENTZER AJDBWW: Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med 297:897-903, 1977 An important study demonstrating the value of pneumococcal polysaccharides in the prevention of pneumococcal infections in children with sickle-cell disease. CrossrefMedlineGoogle Scholar11. BABIOR B: Oxygen-dependent microbial killing by phagocytes. N Engl J Med 298:659-668, 721-725, 1978 Detailed review of the biochemical and enzymatic process by which phagocytic cells kill bacteria, and clinical descriptions of inherited conditions characterized by impaired host defense against bacterial infections, such as chronic granulomatous disease of children. CrossrefMedlineGoogle Scholar12. BESSMAN J: Microcytic polycythemia. Frequency of nonthalassemic causes. JAMA 238:2391-2392, 1977 Elevations of erythrocyte counts like those seen in polycythemia may occur in thalassemia minor, but with different indexes. A high count with a low mean volume in thalassemia minor, alpha or beta, and in polycythemia vera with iron deficiency, distinguishes these from simple iron deficiency anemia. CrossrefMedlineGoogle Scholar13. CRADDOCKFEHRBRIGHAMKRONENBERGJACOB PJKRH: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296:769-774, 1977 The activation of complement results in the aggregation of granulocytes, which has further pathophysiologic consequences. Hemodialysis is one way of activating complement. CrossrefMedlineGoogle Scholar14. DRYSDALEADELMANAROSIOCASAREALEFITZPATRICKHAZARDYOKOTA JTPDPJM: Human isoferritins in normal and disease states. Semin Hematol 14:71-88, 1977 Succinct review of the ferritins isolated from different tissues that have slight molecular differences resulting in variable charges (isoferritins). The origin and the diagnostic significance of serum ferritin are also discussed. MedlineGoogle Scholar15. FORGETNATHAN BD: Molecular pathology of the thalassemias. Adv Intern Med 21:97-128, 1976 Clear, concise, and comprehensive review of the anomalies of hemoglobin synthesis in the various forms of thalassemia, with consideration to such genetically important phenomena as deletions, frame shift mutations, cross-over, and mutation of the termination codon. MedlineGoogle Scholar16. FRANKSCHREIBERATKINSONJAFFE MAJC: Pathophysiology of immune hemolytic anemia. Ann Intern Med 87:210-222, 1977 This National Institutes of Health (NIH) Combined Clinical Staff Conference gives a good summary of the mechanisms of immune hemolytic anemia as viewed by the participants, from whose wide range of experience data are drawn. LinkGoogle Scholar17. LOGUEROSSE GW: Immunologic mechanisms in autoimmune hemolytic disease. Semin Hematol 13:277-289, 1976 This paper outlines the current knowledge on mechanisms of immune hemolysis from in-vitro studies. MedlineGoogle Scholar18. MACDONALD R: Red cell 2,3-diphosphoglycerate and oxygen affinity. Anaesthesia 32:544-553, 1977 Review of the 2,3-diphosphoglycerate, metabolism of its function in modulating oxygen delivery, and its adaptive role in hypoxemia. CrossrefMedlineGoogle Scholar19. MILLERMASONCLYDEMCGINNISS LSDM: The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295:302-304, 1976 A fascinating story to explain the high prevalence of the genotype FyFy. CrossrefMedlineGoogle Scholar20. NIENHUISBENZ AE: Regulation of hemoglobin synthesis during the development of the red cell. N Engl J Med 297:1318-1328, 1371-1381, 1430-1437, 1977 Discussion of theoretic aspects of hemoglobin synthesis, especially the question of the fetal-adult hemoglobin switch, as well as their application to the understanding of the molecular basis of the hemoglobinopathies, particularly thalassemia. CrossrefMedlineGoogle Scholar21. ORKINNATHAN SD: The thalassemias. N Engl J Med 295:710-714, 1976 Despite its shortness this review clearly describes current concepts in the molecular biology of these diseases. CrossrefMedlineGoogle Scholar22. PIERCEKURACHISOFRONIADOUSTAMATOYANNOPOULOS HSKG: Frequencies of thalassemia in American blacks. Blood 49:981-986, 1977 This article brings to attention the frequency of thalassemia in American blacks, the importance of which lies in recognizing the condition as a cause of mild anemia in this group. CrossrefMedlineGoogle Scholar23. PRUZANSKISHUMAK WK: Biological activity of cold-reacting autoantibodies. N Engl J Med 297:583-589, 1977 An excellent summary of our knowledge of cold agglutinins. CrossrefMedlineGoogle Scholar24. SEARS D: The morbidity of sickle cell trait. A review of the literature. Am J Med 64:1021-1036, 1978 Careful and critical review of the literature (296 references) making it appear likely that only severe hypoxia may make the sickle-cell trait symptomatic. CrossrefMedlineGoogle Scholar25. SMITHLANDAW JS: Smokers' polycythemia. N Engl J Med 298:6-10, 1978 Smokers' polycythemia, a frequent diagnosis, should be suspected in any heavy smoker with a high erythrocyte mass. In this study when smoking was stopped, the erythrocyte mass returned to normal. CrossrefMedlineGoogle Scholar26. SONNEBORNPEREZEPSTEINMARTELOPARDO RGMOV: Erythrocytosis associated with the nephrotic syndrome. Arch Intern Med 137:1068-1072, 1977 One of many papers showing that some forms of polycythemia, but not polycythemia vera, may be related to renal disease and excess production of erythropoietin. The bibliography lists the various types of kidney disease that have been associated with polycythemia. CrossrefMedlineGoogle Scholar27. THOMASDU BOULAYMARSHALLPEARSONRUSSELLSYMONWETHERLY-MEINZILKHA DGJTRLGE: Cerebral blood-flow in polycythaemia. Lancet 2:161-163, 1977 This paper reports marked reduction in cerebral blood flow in patients with high hematocrit values in polycythemia vera. The blood flow returned toward normal after repeated phlebotomies. CrossrefMedlineGoogle Scholar28. THOMASDU BOULAYMARSHALLPEARSONRUSSELLSYMONWETHERLEY-MEINZILKHA DGJTRLGE: The effect of haematocrit on cerebral blood-flow in man. Lancet 2:941-943, 1977 This paper indicates the important role of hematocrit values on cerebral blood flow and suggests that the lower hematocrit values provide for relatively better cerebral blood flow. CrossrefMedlineGoogle Scholar29. VAN DER MEULENVAN DER HARTFLEERVON DEM BORNEENGELFRIETVAN LOGHEM FMAACJ: The role of adherence to human mononuclear phagocytes in the destruction of red cells sensitized with non-complement binding IgG antibodies. Br J Haematol 38:541-549, 1978 A good insight into the role of antibody-macrophage interaction in the destruction of erythrocytes in immune hemolytic anemia. CrossrefMedlineGoogle Scholar30. WORWOOD M: The clinical biochemistry of iron. Semin Hematol 14:3-30, 1977 Excellent up-to-date review of the present state of knowledge of iron metabolism. MedlineGoogle Scholar31. ADAMSONFIALKOW JP: The pathogenesis of myeloproliferative syndromes. Br JHaematol 38:299-303, 1978 Reports chromosome aberrations and the distribution of glucose 6-phosphate dehydrogenase isozymes to support the contention that chronic granulocytic leukemia, polycythemia vera, and agnogenic myeloid metaplasia are clonal diseases, arising from a pluripotent stem cell. CrossrefMedlineGoogle Scholar32. BACHVAN ROOD FJ: The major histocompatibility complex. N Engl J Med 295:806-813, 872-878, 927-936, 1976 Comprehensive review of a subject that is becoming increasingly important. CrossrefMedlineGoogle Scholar33. BERARDGALLOJAFFEGREENDEVITA CREIV: Current concepts of leukemia and lymphoma: etiology, pathogenesis, and therapy. Ann Intern Med 85:351-366, 1976 This NIH conference does full justice to its title. LinkGoogle Scholar34. CADMANCAPIZZIBERTINO ERJ: Acute nonlymphocytic leukemia. A delayed complication of Hodgkin's disease therapy: analysis of 109 cases. Cancer 40:1280-1296, 1977 A report of the occurrence of leukemia in patients treated for Hodgkin's disease, an observation that is being made with increasing frequency in patients treated for various neoplasms. CrossrefMedlineGoogle Scholar35. CASELEECLARKSON DBB: Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 63:897-903, 1977 The beneficial effect of two alkylating agents and one cycle dependent agent (vincristine) apparently is derived from the fact that after reduction of the initial tumor burden by the cytotoxic agents, the growth fraction and the mitotic index of the neoplastic cells increase. CrossrefMedlineGoogle Scholar36. CHABNERJOHNSONYOUNGCANELLOSHUBBARDJOHNSONDEVITA BRRGSSV: Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Ann Intern Med 85:149-154, 1976 Describes the National Cancer Institute experiences and helps define current concepts in "staging" of patients with malignant lymphoma of the non-Hodgkin's type. LinkGoogle Scholar37. CHABNERMYERSOLIVERIO BCV: Clinical pharmacology of anticancer drugs. Semin Oncol 4:165-191, 1977 Basic information on the mode of action of drugs used in treating hematologic malignancies and on the rationale of drug combinations. MedlineGoogle Scholar38. CLINELEHRERTERRITOGOLDE MRMD: Monocytes and macrophages: functions and diseases. Ann Intern Med 88:78-88, 1978 An excellent review of monocytes, their descendents, and their functions. Their important role in the effector arm of the immune system is clearly outlined. LinkGoogle Scholar39. COLEMANWILLIAMSFLINTGLATSTEINROSENBERGKAPLAN CCAESH: Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med 297:1249-1252, 1977 An example of the growing incidence of second neoplasms in patients successfully treated for Hodgkin's disease. This report of 680 patients from Stanford, where many current therapeutic modes had their genesis, provides data on incidence rates, actuarial probability of development, and survival. CrossrefMedlineGoogle Scholar40. DEFRONZOCOOKEWRIGHTHUMPHREY RCJR: Renal function in patients with multiple myeloma. Medicine (Baltimore) 57:151-166, 1978 The renal failure in multiple myeloma has been clearly related to the magnitude of Bence Jones proteinuria. Bence Jones proteins have a direct nephrotoxic effect resulting in tubular dysfunction and tubular atrophy without glomerular damage. CrossrefMedlineGoogle Scholar41. FISHERDEVITAJOHNSONSIMONYOUNG RVBRR: Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 63:177-182, 1977 Combination chemotherapy trials have provided excellent results in a major subset group of patients with advanced diffuse histiocytic lymphoma. This reports the results of clinical trials and defines factors that appear to affect prognosis. CrossrefMedlineGoogle Scholar42. FRENKELKITCHENS ER: Applicability of an enzymatic quantitation of methylmalonic, propionic, and acetic acids in normal and megaloblastic states. Blood 49:125-137, 1977 Studies of the biologic role of the intermediates in the B12- dependent metabolic pathway (of propionate catabolism) and their use in the differential diagnosis of megaloblastic anemia. CrossrefMedlineGoogle Scholar43. GALECLINE RM: High remission-induction rate in acute myeloid leukaemia. Lancet 1:497-499, 1977 A brief report of the complete remissions obtained in acute myeloid leukemia: the duration of remission and survival, and drug toxicity. CrossrefMedlineGoogle Scholar44. GONZALEZTRUJILLOALEXANIAN FJR: Acute leukemia in multiple myeloma. Ann Intern Med 86:440-443, 1977 Eleven (2.3%) of 476 patients with multiple myeloma treated with melphalan-prednisone developed acute myelogenous leukemia or sideroblastic anemia. Median duration of treatment was 3 years. In all patients studied evidence of chromosomal damage was noted. LinkGoogle Scholar45. GRALNICKGALTONCATOVSKYSULTANBENNETT HDDCJ: Classification of acute leukemia. Ann Intern Med 87:740-753, 1977 Classification of acute leukemia for the general internist. The importance of careful morphologic observation and histochemical differentiation and the success of the proposed system in the hands of the proposers are documented. LinkGoogle Scholar46. GREENBERGMARABAXBROSSELSCHRIER PBIRS: The myeloproliferative disorders. Correlation between clinical evolution and alterations of granulopoiesis. Am J Med 61:878-891, 1976 Exemplifies the importance and usefulness of cell cultures to the clinical understanding of the myeloproliferative disorders. CrossrefMedlineGoogle Scholar47. KUNGLONGMCCAFFREYRATLIFFHARRISONBALTIMORE PJRRTD: Terminal deoxynucleotidyl transferase in the diagnosis of leukemia and malignant lymphoma. Am J Med 64:788-794, 1978 Describes the clinical usefulness of terminal transferase measurement in classifying patients with various leukemias and lymphomas. CrossrefMedlineGoogle Scholar48. KYLE R: Monoclonal gammopathy of undetermined significance. Amer J Med 64:814-826, 1978 Drawing on the rich experience at the Mayo Clinic, Dr. Kyle reviews the dynamics of benign monoclonal gammopathy in 241 patients. Assurance of benignity is achieved mainly by long-term observation. CrossrefMedlineGoogle Scholar49. LINMANBAGBY JG: The preleukemic syndrome (hemopoietic dysplasia). Cancer 42:854-864, 1978 Describes the clinical and laboratory features of the hematologic disorder (preleukemia) that precedes the development of overt acute leukemia, the criteria for diagnosis, and its course and management. CrossrefMedlineGoogle Scholar50. NATHWANIKIMRAPPAPORT BHH: Malignant lymphoma, lymphoblastic. Cancer 38:964-983, 1976 The clinical, laboratory, and morphologic definition of this newly categorized variant of malignant lymphoma with T-cell characteristics, lymphoblastic lymphoma (convoluted cell lymphoma of Lukes). Recent multiagent chemotherapy trials have suggested this may be a curable lesion. CrossrefMedlineGoogle Scholar51. NEIMANDERVANHAUDENSCHILDJAFFE RPCR: Angioimmunoblastic lymphadenopathy. An ultrastructural and immunologic study with review of the literature. Cancer 41:507-518, 1978 Report of the clinical laboratory features of immunoblastic (or angioimmunoblastic) lymphadenopathy in a review of the literature and a description of the structural and immunologic characteristics seen in recent cases. CrossrefMedlineGoogle Scholar52. PANGALISMORANRAPPAPORT GEH: Blood and bone marrow findings in angioimmunoblastic lymphadenopathy. Blood 51:71-83, 1978 An important documentation of the specific and nonspecific findings in blood and bone marrow associated with this newly described variant of lymph node structure. CrossrefMedlineGoogle Scholar53. RAPPHEWETSON CJ: Infectious mononucleosis and the Epstein-Barr virus. Am J Dis Child 132:78-86, 1978 A concise review of the classical clinical syndromes of mononucleosis that relates the classical laboratory findings to our current knowledge of the sequential serologic findings on the clinical role of Epstein-Barr virus. MedlineGoogle Scholar54. ROSENTHALCANELLOSDEVITAGRALNICK SGVH: Characteristics of blast crisis in chronic granulocytic leukemia. Blood 49:705-714, 1977 Reviews the clinical and hematologic features of 73 patients with the terminal phase ("blast transformation") of Philadelphia-chromosome-positive chronic granulocytic leukemia. The lymphoblastic and myeloblastic subgroups are defined and therapeutic trials discussed. CrossrefMedlineGoogle Scholar55. ROWLEY J: Chromosomes in leukemia and lymphoma. Semin Hematol 15:301-319, 1978 An excellent review describing the different types of chromosome abnormalities that occur in acute and chronic myeloid leukemia, acute lymphoblastic leukemia, and malignant lymphoma. MedlineGoogle Scholar56. SIMONEAURHUSTUVERZOSAPINKEL JRHMD: Three to ten years after cessation of therapy in children with leukemia. Cancer 42:839-844, 1978 Report of the course and survival in a large group of patients with acute lymphoblastic leukemia after cessation of treatment. CrossrefMedlineGoogle Scholar57. SHUSTIKBERGSAGELPRUZANSKI CDW: κ and λ light chain disease: survival rates and clinical manifestations. Blood 48:41-51, 1976 Thorough analysis of the findings in 97 patients whose myeloma produced only light chains (approximately 20% of all patients with myeloma). Lambda Bence Jones protein was associated with an unexplained poorer prognosis than was kappa Bence Jones protein. CrossrefMedlineGoogle Scholar58. SOLOMON A: Bence-Jones proteins and light chains of immunoglobulins. N Engl J Med 294:17-23, 91-98, 1976 Although this review is mainly concerned with the biochemistry of immunoglobulins and the relation of the light chain to the whole immunoglobulin structure, it provides an understanding of the overproduction of light chains in immunoproliferative diseases. CrossrefMedlineGoogle Scholar59. STROBER S: T- and B-cells in immunologic diseases. Am J Clin Pathol 68:671-678, 1977 This paper, part of a supplement on the diagnostic approaches to immune and autoimmune reactions, provides a succinct review of the issues related to characterization assays of B and T cells and null or third-party cells as well as related subset populations. MedlineGoogle Scholar60. THEMLLOVEBEGEMANN HRH: Factors in the pathomechanism of chronic lymphocytic leukemia. Annu Rev Med 28:131-141, 1979 An excellent review of the cellular characteristics of chronic lymphocytic leukemia and the kinetics of the disease. CrossrefGoogle Scholar61. WALDMANNBLAESEBRODERKRAKAUER TRSR: Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med 88:226-238, 1978 This NIH conference deals with an increasingly important phenomenon that has pathogenetic significance in autoimmune hemolytic anemia and in the immunologic deficiency of myeloma. LinkGoogle Scholar62. WELLERGLATSTEINKAPLANROSENBERG SEHS: Initial relapses in previously treated Hodgkin's disease. I. Results of second treatment. Cancer 37:2840-2846, 1976 Review of the clinical data in 243 consecutive cases of Hodgkin's disease that relapsed after primary treatment with recommendations on the management of such cases in clinical relapse. CrossrefMedlineGoogle Scholar63. WIERNIK P: Advances in the management of acute nonlymphocytic leukemia. Arch Intern Med 136:1399-1403, 1976 Describes the effect of specific chemotherapy and supportive care on the improvement of remission rate, remission duration, and survival. CrossrefMedlineGoogle Scholar64. ZIEGLER J: Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. N Engl J Med 297:75-80, 1977 Summary of the clinical patterns of the American form of Burkitt's lymphoma with data on the therapeutic results of an extensive collaborative treatment program. CrossrefMedlineGoogle Scholar65. AHNBYRNESHARRINGTONCAYERSMITHBRUNSKILLPALL YJWMDDL: The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. N Engl J Med 298:1101-1107, 1978 Specific therapy delivered to platelet-destroying macrophages by drug-laden platelets has been successful in treating refractory cases of idiopathic thrombocytopenic purpura. CrossrefMedlineGoogle Scholar66. CEDERBAUMBLATTROBERTS APH: Intravascular coagulation with use of human prothrombin complex concentrates. Ann Intern Med 84:683-687, 1976 Although prothrombin complex concentrates may be lifesaving in treatment of congenital and acquired coagulation abnormalities, their use is attended by frequent complications including disseminated intravascular coagulation. LinkGoogle Scholar67. GRALNICKCOLLERSHULMANANDERSENHILGARTNER HBNJM: Factor VIII. Ann Intern Med 86:598-616, 1977 This comprehensive update reviews the differential diagnosis of hemophilia A and von Willebrand's disease, discusses new evidence for the molecular bases of these diseases, addresses the problem of anti-factor VIII antibodies, and cites the therapeutic advances in overall care of hemophiliacs. LinkGoogle Scholar68. JACKSON C: The biochemistry of prothrombin activation. Br J Haematol 39:1-8, 1978 Brief and succinct description of the molecular action of vitamin K and the vitamin K antagonists. CrossrefMedlineGoogle Scholar69. JAFFE E: Endothelial cells and the biology of factor VIII. N Engl J Med 296:377-383, 1977 The cells lining normal blood vessels have important roles in hemostasis and in prevention of thrombosis that recently have been elucidated as a result of successful tissue culture of human vascular endothelium. CrossrefMedlineGoogle Scholar70. JOBIN F: Acetylsalicylic acid, hemostasis and human thromboembolism. Semin Thromb Hemostas 4:199-240, 1978 Review covering the role of prostaglandins in hemostasis, and the effect of aspirin on platelet function and its experimental use in preventing venous thromboembolism, reducing coronary artery disease, preventing embolization from prosthetic heart valves, reducing closure of arteriovenous shunts, and managing cerebrovascular disorders. CrossrefMedlineGoogle Scholar71. KASPERØSTERUDMINAMISHONICKRAPAPORT CBJWS: Hemophilia B: characterization of genetic variants and detection of carriers. Blood 50:351-66, 1977 Heterogeneity in hemophilia B, as in factor VIII-related diseases, gives important clues to mechanisms of coagulation factor function. CrossrefMedlineGoogle Scholar72. MAJERUSMILETICH PJ: Relationships between platelets and coagulation factors in hemostasis. Annu Rev Med 29:41-49, 1978 An excellent synthesis of the interactions between cellular and plasma factors in blood coagulation. CrossrefMedlineGoogle Scholar73. MARX J: Blood clotting: the role of prostaglandins. Science 196:1072-1075, 1977 Succinct review of the increasingly important role of prostaglandins in coagulation. CrossrefMedlineGoogle Scholar74. MONCADAHIGGSVANE SEJ: Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1:18-20, 1977 The first demonstration of generation of the vascular hormone prostacyclin (PGX or PGI2) by human tissue, this paper presents the concept that prostacyclin may be a natural antithrombotic factor. CrossrefMedlineGoogle Scholar75. NOSSEL H: Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis. N Engl J Med 295:428-432, 1976 Measurement of specific fibrinogen cleavage products, indicating activation of intravascular thrombin or plasmin, is a promising means for evaluating activation of coagulation, with many possible clinical applications. CrossrefMedlineGoogle Scholar76. ROSENBERG R: Biologic actions of heparin. Semin Hematol 14:427-440, 1977 Review of the mechanisms of heparin action, the role of antithrombin-3 heparin cofactor, and implications for clinical use of heparin. MedlineGoogle Scholar77. RossGLOMSET RJ: The pathogenesis of atherosclerosis. N Engl J Med 295:369-376, 420-425, 1976 This two part review of recent experimental data relates arterial endothelial injury, platelet-derived factors, and hypercholesterolemia as important contributors to the pathogenesis of atherosclerosis. CrossrefMedlineGoogle Scholar78. SACKLEVINBELL GJW: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56:1-37, 1977 A comprehensive review of the chronic disseminated intravascular coagulation syndrome commonly associated with visceral neoplasm, which may present differently from acute disseminated intravascular coagulation and require different therapy. CrossrefMedlineGoogle Scholar79. SCHLEIDERNACHMANJAFFECOLEMAN MREM: A clinical study of the lupus anticoagulant. Blood 48:499-509, 1976 The lupus anticoagulant, a fairly common finding in abnormal coagulation studies, is analyzed. Half the patients had signs of lupus erythematosus. CrossrefMedlineGoogle Scholar80. STENFLO J: Vitamin K, prothrombin and γ-carboxyglutamic acid (editorial). N Engl J Med 296:624-625, 1977 A brief but concise review of our current understanding of the mechanism of action of the vitamin K-dependent procoagulants, the role of calcium, and the pharmacologic effects of the vitamin K antagonists. CrossrefMedlineGoogle Scholar81. THOMASBUCKNERBANAJICLIFTFEFERFLOURNOYGOODELLHICKMANLERNERNEIMANSALESANDERSSINGERSTEVENSSTORBWEIDEN ECMRANBRKPGJJMRP: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49:511-533, 1977 The role of allogeneic bone marrow transplantation is placed in context by this study of 100 patients with acute leukemia. The problems and results are carefully outlined. CrossrefMedlineGoogle Scholar82. : A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 299:53-59, 1978 An important cooperative evaluation of antiplatelet prophylactic therapy in patients with threatened stroke, in which aspirin benefited men, whereas sulfinpyrazone was without effect. Women did not benefit from this therapy. CrossrefMedlineGoogle Scholar83. COON W: Epidemiology of venous thromboembolism. Ann Surg 186:149-164, 1976 An extensive review on the incidence of venous thromboembolism and its sequelae. The difficulty in obtaining accurate data is stressed. An important section analyzes risk factors including sex, age, family history, oral contraceptive use, pregnancy, heart disease, cancer, varicose veins, and past history of thromboembolism. CrossrefGoogle Scholar84. COTTONROBERTS LV: The prevention of deep vein thrombosis with particular reference to mechanical methods of prevention. Surgery 81:228-235, 1977 Review of data that document venous stasis and pooling in the soleal plexus during surgery, emphasizing mechanical methods for prophylaxis of venous thromboembolism that seem to be as good as minidose heparin and dextran but have no harmful side-effects. MedlineGoogle Scholar85. : Prevention of venous thromboembolism in surgical patients by low-dose heparin. Circulation 55:423A-426A, 1977 A concise report reviewing the international trial wherein low-dose heparin was shown to be effective in reducing pulmonary embolism and deaths due to pulmonary embolism after surgery. Specific recommendations are made on appropriate prophylaxis. Google Scholar86. HARRISSALZMANATHANASOULISWALTMANDESANCTIS WECAR: Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 297:1246-1248, 1977 This small study shows that aspirin was effective prophylaxis against venous embolism in male patients undergoing hip surgery but apparently did not benefit female patients. Other studies on arterial thrombosis appear to confirm this sex difference in therapeutic response. CrossrefMedlineGoogle Scholar87. HIRSH J: Hypercoagulability. Semin Hematol 14:409-426, 1977 A clear overview of changes in coagulation factor levels, factor turnover rates, clearance mechanisms, and platelet function that may lead to enhanced coagulation. MedlineGoogle Scholar88. PACKHAMMUSTARD MJ: Clinical pharmacology of platelets. Blood 50:555-573, 1977 Many drugs affect platelet function. This clearly presented review details current understanding of drug-platelet interactions, pointing out those clinically important in altering hemostasis and those potentially useful in preventing thrombosis. CrossrefMedlineGoogle Scholar89. SIMONHYERSGASTONHARKER TTJL: Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 39:111-120, 1978 This study shows that heparin clearance is significantly accelerated in patients with pulmonary embolism. This observation confirms clinical lore indicating that the dose of heparin needed to adequately prolong the partial thromboplastin time on Day 1 in patients with pulmonary embolism may cause hemorrhage on Day 3 or 4. CrossrefMedlineGoogle Scholar90. STEELEELLISGENTON PJE: Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. Am J Med 64:441-445, 1978 Patients with recurrent thromboembolism despite apparently optimal vitamin K antagonist anticoagulation were found to have abnormalities of platelet survival, fibrinolytic activity, and fibrinogen turnover. Sulfinpyrazone therapy restored platelet survival toward normal. CrossrefMedlineGoogle Scholar91. Streptokinase (editorial). Br Med J 2:927-928, 1977 A brief review of the actions, dangers, indications, and contraindications for the use of the fibrinolytic agents. MedlineGoogle Scholar92. DUQUESNOYFILIPASTER RDR: Influence of HLA-A2 on the effectiveness of platelet transfusion in alloimmunized thrombocytopenic patients. Blood 50:407-412, 1977 This study opens new approaches to broader selection of donors for platelet transfusion to immunized patients by showing that a single common histocompatibility leukocyte antigen-A allele dominates transfusion effectiveness. CrossrefMedlineGoogle Scholar93. GRADEY G: Transfusions and hepatitis: update in '78 (editorial). N Engl J Med 298:1413-1415, 1978 This editorial reviews the status of hepatitis and transfusions and points out the role of non-A, non-B transfusional hepatitis. CrossrefMedlineGoogle Scholar94. GOLDFINGER D: Acute hemolytic transfusion reactions—a fresh look at pathogenesis and considerations regarding therapy. Transfusion 17:85-98, 1977 Argues that the pathogenesis of acute hemolytic transfusion reaction primarily revolves about the induction of disseminated intravascular coagulation and proposes that treatment be directed to support of the circulation and management of disseminated intravascular coagulation including the use of heparin. CrossrefMedlineGoogle Scholar95. HERZIGHERZIGGRAWBULLRAY RGRMK: Successful granulocyte transfusion therapy for gram-negative septicemia. N Engl J Med 296:701-705, 1977 The ability of granulocyte transfusion therapy to aid in the cure of gram-negative septicemia in the neutropenic host is carefully documented. Some of the rules about the use of granulocytes as we now understand them are propounded. CrossrefMedlineGoogle Scholar96. LANINGHAM J: Partial plasma exchange, an adjunct in therapy to complex clinical problems. Transfusion 17:547-554, 1977 The blood bank can remove harmful substances, both soluble and cellular, from the blood and improve circumstances as diverse as the hyperviscosity syndrome, hemorrhage due to circulating anticoagulants, and immune disorders associated with circulating immune complexes. CrossrefMedlineGoogle Scholar97. PINEDATASWELLBRZICA AHS: Delayed hemolytic transfusion reaction. An immunologic hazard of blood transfusion. Transfusion 18:1-7, 1978 Delayed hemolytic transfusion reaction can present the physician with a diagnostic puzzle—hemolysis and its sequelae occurring several weeks after transfusion. Twenty-three cases are reviewed. CrossrefMedlineGoogle Scholar98. TAFTBABCOCKSCHARFMANTARTAGLIA ERWA: Plateletpheresis in the management of thrombocytosis. Blood 50:927-933, 1977 Platelet pheresis using mechanical devices available in blood banks results in prompt lowering of platelet levels and avoidance of hemorrhagic and thrombotic complications associated with elevated platelet counts in patients with myeloproliferative disorders. CrossrefMedlineGoogle Scholar99. VALERI C: Current concepts of blood transfusion. J Oral Surg 35:707-712, 1977 A very clearly and simply written review of current blood banking practices: component preparation, viability of cellular elements during storage, management of specific blood bank problems, complications of transfusion, and the current and future use of frozen blood and autotransfusion. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: AMERICAN COLLEGE OF PHYSICIANS Philadelphia, Pennsylvania*Stanley L. Schrier, M.D., Chairman; Paul A. Chervenick, M.D.; Eugene P. Frenkel, M.D.; Paul Heller, M.D.; Wendell F. Rosse, M.D.; Ralph O. Wallerstein, M.D.; and Babette Weksler, M.D.†Computer literature-file of the National Library of Medicine, Bethesda, Maryland, consulted through the Regional Medical Library service Library of the College of Physicians of Philadelphia, with the technical assistance of Ruthanne Henner. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCarbohydrates 1 May 1979Volume 90, Issue 5Page: 860-865KeywordsComputersHematology and oncologyLibraries ePublished: 1 December 2008 Issue Published: 1 May 1979 PDF downloadLoading ...